Migraine Therapeutics in Development

Slides:



Advertisements
Similar presentations
TREATMENTS FOR ACUTE MIGRAINE : WHAT ’ S ON THE HORIZON ? Mark Weatherall BASH Hull 2011.
Advertisements

Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials by Michel D. Ferrari, Krista I. Roon, Richard B.
Anti-Migraine Drugs Brian Lich April 3 rd, Overview Migraines: What are they? Symptoms? Causes? Migraines: What are they? Symptoms? Causes? History:
Acute treatment of migraine Dr Mark Weatherall London Headache Centre 2010.
AprepitantAprepitant Division of Gastrointestinal and Coagulation Drug Products Division of Gastrointestinal and Coagulation Drug Products Center for Drug.
MOnoclonal antibodies and potential applications in migraine
Pseudomonas Infection in Cystic Fibrosis
Systemic Lupus Erythematosus
CLINICAL DILEMMAS IN HEART FAILURE:
IL-12 and IL-23.
Olivia Moderator: Dr. Yugrakh EBN February 2018
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Unraveling Clinical Developments in NASH
Updates in the Clinical Science of CGRP Antagonism for the Treatment of Migraine.
Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.
An Update on Oral Prostanoids: Advancing Care for PAH?
A CASE CHALLENGE IN HFrEF:
Migraine Prevention Therapy: Avoiding Overuse of Medications
New Directions in iTTP.
Obesity and Dyslipidemia: How Would You Treat?
Case Challenges in Chronic Migraine
New Treatments for CTEPH
PARP Inhibitors and Cancer: What Do You Need to Know?
Insight Into the Latest Findings in Migraine
The Vicious Cycle of Chronic Migraine How Can the Physician Help?
Updates in Migraine From a 2018 American Headache Meeting
Translating Atopic Dermatitis
Diagnostic and Management Challenges in Patients With Chronic Migraine
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Postpartum Depression
The Biology Behind BCL2 as a Target in Myeloma
Next-Gen Psoriasis Therapies:
PCSK9 Inhibitors and Cardiovascular Outcomes
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Gene Therapy: Past, Present, and Future
Drug-Coated Balloons:
Reversal Strategies for VKA: Truths and Misconceptions
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Demystifying the Science of Monoclonal Antibodies in Migraine
CGRP Antibodies in Migraine
Current and Future Perspectives on Migraine Prevention Therapy
Advancing the Treatment of IBD With Biologics
Breaking New Ground With Migraine Prevention Therapies
The Evolving Treatment Landscape in Atopic Dermatitis
Aspirin and Cardioprevention in 2018
Oral Prostanoids and PAH
Getting to Grips With the Science of CGRP and Migraine
Implications of Emerging Treatments for Beta-Thalassemia
Best Practices in SMA.
Defining the Clinical Value of Endpoints Used in Migraine Trials
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?
New Paradigms in M0 CRPC.
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Pathogenesis of IBD, and the Role of Biologic Therapies
The Biologic Basis of Migraine
Targeting IL-23 for Therapeutic Longevity in Psoriasis
PAH Pathways: What Do the Data Tell Us?”
Clinical Comparisons in CTEPH
A Closer Look.
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Diagnostic Criteria Migraine Without Aura
Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know.
A New Era in Migraine Prevention
PCSK9 Inhibitors and Real-World Evidence
Advances in Portopulmonary Hypertension
Meet the JAKs.
2019 MPhA Annual Networking Learning Event & MTM Symposium
You Don't Know JAK in IBD.
Presentation transcript:

Migraine Therapeutics in Development

Migraine Pathophysiology

First Targeted Acute Therapy Approved for Migraine The Triptans

Sumatriptan 10 mg With a Permeation Enhancer Phase 2 Study

Sumatriptan 10 mg With a Permeation Enhancer Freedom From MBS

Adhesive Dermally Applied Microarray

ADAM Zolmitriptan

ADAM Zolmitriptan Freedom From MBS

ADAM Zolmitriptan Safety

The Role of Serotonin in Migraine Lasmiditan

Lasmiditan SAMURAI and SPARTAN Phase 3 Studies

Lasmiditan Safety

Calcitonin Gene-Related Peptide

CGRP Role in Migraine Pathogenesis

CGRP-Receptor Antagonists GEPANTs

Rimegepant Study 302, Phase 3 Study Design

Rimegepant Study 302 Primary Endpoints

Rimegepant Study 302 Secondary Endpoints

Rimegepant Safety

Ubrogepant ACHIEVE II, Phase 3 Study

Ubrogepant ACHIEVE II Primary Endpoints

Ubrogepant ACHIEVE II Secondary Endpoints

Ubrogepant Safety

Conclusions

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.